The Brazilian Ministry of Health temporarily suspended its dengue vaccination strategy using the Butantan-DV vaccine on Monday, June 8, 2024 [1].
The suspension occurs as Brazil seeks to increase its autonomy in combating dengue fever. A halt in the rollout of a domestically developed vaccine could delay public health goals and impact confidence in the national immunization program.
Officials took the action after the post-vaccination surveillance system identified 42 serious adverse reactions [1]. The Ministry of Health suspended the strategy nationwide to investigate these reports [1].
Medical professionals are now advising those who have already received the vaccine to monitor their health. Lorena de Castro Diniz said vaccinated individuals should be alert for symptoms such as fever, vomiting, and headaches during the 21 days following the application [1].
Patients experiencing these symptoms are urged to seek medical attention immediately [1]. The surveillance period of 21 days is critical for identifying delayed reactions to the Butantan-DV formula [1].
The Butantan-DV vaccine was intended to be a cornerstone of the country's health strategy. Previous reports indicated that the Sistema Único de Saúde (SUS) planned to offer the Brazilian-made vaccine starting in 2026 [3].
While some reports suggested the immunization strategy was being announced as recently as Tuesday, June 9, 2024 [2], the Ministry of Health's suspension on June 8 precedes those claims [1].
“The Ministry of Health temporarily suspended its dengue vaccination strategy using the Butantan-DV vaccine.”
The suspension of the Butantan-DV vaccine highlights the tension between the urgent need for dengue prevention and the rigorous safety requirements of vaccine rollout. Because this is a domestically produced vaccine, the outcome of the investigation will determine whether Brazil can achieve the goal of pharmaceutical autonomy or if it must rely on more expensive international alternatives to protect its population.
